[Results of a cooperative study of bromazepam involving 3.401 ambulatory psychiatric patients and 8.191 patients from general practice (author's transl)].
The value of this study lies in the large number of patients treated by general practitioners who accepted to follow a very strict protocol. Statistical analysis of the results was performed with the help of a computer. This is probably the first time that an anxiolytic drug is investigated in that way. A fairly accurate clinical profile of the anxious patient could be drawn from a total of 11.592 cases, including distribution by sex and age, characteristics of the anxiety and symptoms by which it is expressed or accompanied, evaluation of the symptoms by the patients themselves, and nosological context. The results recorded confirm the quality of the anxiolytic effects of bromazepam in all forms of anxiety, with the additional benefit of relief from anxiety-induced inhibitions. Precise information was obtained concerning the optimal dosage and duration of treatment and the incidence of untoward reactions.
D000328:Adult; D000553:Ambulatory Care; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000188:drug therapy* / Q000523:psychology; D001960:Bromazepam / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D005194:Family Practice; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009497:Neurotic Disorders / Q000188:drug therapy; D011570:Psychiatry
D014151:Anti-Anxiety Agents; D001960:Bromazepam
Bilan de l'étude coopérative du bromazépam portant sur 3.401 observations de psychiatrie ambulatoire et 8.191 observations de médecine praticienne.